For EML, we factor in 19%, 33.1% sales, PAT CAGR, respectively, in FY2123E. The company is seen delivering healthy double-digit volume growth in RE along with continued VECV outperformance, with margins undergoing a sedate recovery. We maintain HOLD and value EML at | 2,970 on SOTP basis...